Tumor Response Assessment
Tumor Response Assessment - Related Videos
11:31
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
0 Views •
Cited by 11 •
2016
We describe a method for the detection of tumor nodule development in the lungs of an adenocarcinoma mouse model using micro-computed tomography and its use for monitoring changes in nodule size over time and in response to treatment. The accuracy of the assessment was confirmed with end-point histological quantification.
09:43
Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
0 Views •
Cited by 22 •
2017
The transplantation of cancer cells is an important tool for the identification of cancer mechanisms and therapeutic responses. Current techniques depend on immune-incompetent animals. Here, we describe a method to transplant zebrafish tumor cells into immune-competent embryos for the long-term analysis of tumor cell behavior and in vivo drug responses.
04:13
A Technique to Assess the In Vivo Localization of Tumor-Specific Antibodies
0 Views •
2025
This video demonstrates a technique to study the in vivo localization of tumor-specific antibodies in a mouse tumor xenograft model. Upon subcutaneously injecting cancer cells into mice for tumor formation, fluorescently-labeled antibodies are injected that bind to tumor-specific receptors, enabling in vivo assessment of antibody localization via imaging.
11:09
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
0 Views •
Cited by 104 •
2010
Luciferase-modified human brain tumor xenografts can be established intracranially in athymic mice, with subsequent monitoring of tumor growth and response to therapy using bioluminescence imaging. In combination with survival analysis, bioluminescence monitoring is an essential research tool for pre-clinical testing of therapies being considered for treating brain tumors.
01:18
Thermally Responsive Biopolymer-Based Inhibition of Tumor Progression in a Rat Model
0 Views •
2025
Begin with an anesthetized rat bearing a brain tumor composed of proliferating tumor cells.Expose the rat’s skull and create a hole to reveal the brain region with the tumor.Take a thermally responsive biopolymer fused with a cell-penetrating peptide and an inhibitor of c-myc, an oncogenic protein.Inject the biopolymer into the femoral vein of the hind limb for delivery to the brain.Apply infrared light through the skull hole to heat the tumor site, which induces biopolymer aggregation along...
FAQs
RECIST organizes findings into complete response, partial response, stable disease, or progressive disease by applying standardized criteria to changes observed against baseline findings. These categories create a consistent language for reporting tumor status, allowing clinicians and investigators to compare outcomes across assessments, support clinical-trial endpoints, and identify when a treatment appears ineffective.
A tumor may show a meaningful treatment-related change in metabolic activity or another functional feature before its measured size changes substantially. Including these signals can provide earlier evidence of treatment effect than size alone. This is particularly relevant when conventional size measurements might not yet reflect altered disease activity.
Imaging can assess size or metabolic activity, while physical examination, pathology, and molecular or blood-based biomarkers add other evidence about disease status. Combining these sources allows assessment to reflect more than dimensions alone. The resulting interpretation can better inform treatment selection and follow-up when different measures do not change at the same pace.
Repeated assessments can show whether an initially favorable response is maintained or whether disease burden begins to increase again. Such changes may signal treatment resistance or recurrence, prompting clinicians to reconsider subsequent care. The value comes from interpreting current findings in relation to earlier measurements rather than treating a single examination as the complete picture.
Assessment begins with baseline findings, followed by evaluation during or after treatment using appropriate available measures. Clinicians compare tumor size, metabolic activity, or disease burden with that baseline, then integrate imaging, examination, pathology, and biomarker information. The findings are categorized or interpreted to guide treatment decisions, continued monitoring, or subsequent care.
In oncology research, standardized response categories provide measurable clinical-trial endpoints, while in practice the findings help clinicians select treatment and plan subsequent care. Response patterns also contribute to prognosis by showing how disease changes over time. This makes the assessment useful both for comparing therapies systematically and for tailoring decisions to an individual patient’s observed disease status.